Urgent clinical needs and low substitutability
In order to facilitate timely purchase of NRDL (National Reimbursement Drug List) negotiated drugs by the vast number of patients, NHSA (National Healthcare Security Administration) organized experts to select the first batch of 19 drugs with urgent clinical needs and low substitutability from the new negotiated drugs in 2020, and arranged relevant enterprises to submit specific information of medical institutions providing such drugs, so that insured patients can receive medical treatment and purchase drugs easily. Ameile® (Almonertinib Mesilate Tablets) and Hansoh Xinfu® (Flumatinib Mesylate Tablets) are among such drugs.
List of medical institutions is available on NHSA platform
NHSA has created a Reference List of Medical Institutions Providing Some Negotiated Drugs Newly Included in National Reimbursable Drug List 2020 (First Batch), and set up the query mode in the "Drug Catalogue" module of the "NHSA Service Platform (APP)", which now allows the query of medical institutions providing Ameile® and Hansoh Xinfu®. The query method is as follows:
Step 1: Download "NHSA Service Platform (APP)"
Download for Android Download for iOS
Step 2: Click "Drug Catalogue" and select "Reference List of Medical Institutions Providing Some Negotiated Drugs Newly Included in National Reimbursable Drug List 2020 (First Batch)"
Step 3: Select Ameile/Hansoh Xinfu - Select Region, to view the information of designated medical institutions and retail pharmacies
For more information, please refer to official news from NHSA.
About Ameile® (Almonertinib Mesilate Tablets)
Ameile® (Almonertinib Mesilate Tablets) is China's first original third-generation EGFR-TKI innovative drug independently developed by Hansoh Pharma, and also the world's first third-generation EGFR-TKI with median progression-free survival (MPFS) exceeding one year (second-line use). In December 2020, Ameile® was officially included in the National Reimbursable Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2020), and on March 1, 2021, the new version of the National Reimbursable Drug List was officially implemented, which will help improve the accessibility and affordability of domestic innovative drugs as well as the standardization of clinical treatment, thus benefiting more patients and bringing more social benefits.
About Hansoh Xinfu® (Flumatinib Mesylate Tablets)
Hansoh Xinfu® (Flumatinib Mesylate Tablets) is the first novel second-generation chronic myeloid leukemia drug independently developed in China. "Bi-directionally optimized" in terms of efficacy and safety, it is a "second-generation +" tyrosine kinase inhibitor (TKI), with higher response rate, faster and deeper response, and better tolerance. Starting from March 1, 2021, the new version of the National Reimbursable Drug List has come into effect; Hansoh Xinfu® is now a reimbursable drug, from which more patients will benefit.